Doose Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Doose Syndrome Market Outlook

Thelansis’s “Doose Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Doose Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Doose Syndrome Overview

Doose Syndrome, formerly known as Myoclonic Astatic Epilepsy and Myoclonic Atonic Epilepsy, is an extremely uncommon form of seizures that impacts young children in their early years. Various types of seizures characterize this syndrome. Myoclonic seizures involve rapid jerking movements that can manifest in the trunk or axis of the body. Sometimes, these jerks can lead to a myoclonic drop, where the individual appears to be forcefully propelled to the ground. There can also be subtler jerks perceived subjectively by the child or expressed through subtle vocalizations. Astatic or atonic seizures are possible, causing momentary loss of muscle tone, often resulting in head nodding. However, the child typically regains balance swiftly, preventing a complete fall. Children afflicted by Doose Syndrome can experience long-term health repercussions, including physical injuries and respiratory challenges. Immediate medical attention might also be necessary. Distinguishing between Doose syndrome and other seizure disorders like benign myoclonic epilepsy, severe myoclonic epilepsy, atypical benign partial epilepsy of childhood, and Lennox-Gastaut Syndrome (LGS). Severe myoclonic epilepsy (Dravet syndrome) is notably separate from Doose syndrome. Even though both might commence with febrile seizures in cognitively normal children, Dravet syndrome often involves partial seizures and distinctive EEG focal findings absent in Doose syndrome. Unlike Doose syndrome, severe myoclonic epilepsy prominently features myoclonus and rarely includes an atonic element. Historically, Doose syndrome has been recognized as difficult to manage effectively. The prognosis for Doose syndrome can vary, leaning toward favorable or unfavorable outcomes. The unfavorable prognosis in Doose syndrome is marked by generalized tonic-clonic seizures in the first two years of life, early development of myoclonic status, absence or convulsive status epilepticus, tonic seizures, persistent abnormal theta rhythm in the background, and absence of a background alpha rhythm. Poor prognosis indicators also encompass sleep-onset seizures and the emergence of myoclonic seizures after age four, suggesting continued excitatory pathway activity. In children with a grim prognosis, cognitive impairment tends to align with resistance to anticonvulsants and the ketogenic diet.

• The prevalence of Doose Syndrome is remarkably low, typically affecting only 1 to 2 out of every 100 children diagnosed with epilepsy. Moreover, boys are more prone to developing Doose Syndrome compared to girls.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: